Contact
searchSearch
HMP Global

From the Editor

Letter from the Editor
Optimizing Efficiency and Outcomes in the Electrophysiology Lab
04/01/2025
Bradley P. Knight, MD, FACC, FHRS
Improving efficiency in the EP lab is an important goal. By striving to operate at the top of the efficiency/outcomes curve, one can minimize complications and ultimately improve outcomes.
Improving efficiency in the EP lab is an important goal. By striving to operate at the top of the efficiency/outcomes curve, one can minimize complications and ultimately improve outcomes.
Improving efficiency in the EP...
04/01/2025
EP Lab Digest
Letter from the Editor
Genetic Testing for Early-Onset Atrial Fibrillation: When Is It Necessary?
03/10/2025
Bradley P. Knight, MD, FACC, FHRS
As evidence grows that these patients can be found to have a gene mutation which has a clinically meaningful impact on prognosis and treatment, it is likely that guidelines will recommend genetic testing more strongly in young patients.
As evidence grows that these patients can be found to have a gene mutation which has a clinically meaningful impact on prognosis and treatment, it is likely that guidelines will recommend genetic testing more strongly in young patients.
As evidence grows that these...
03/10/2025
EP Lab Digest
Letter from the Editor
Vertebral Vein Electrical Stimulation to Provoke Ventricular Ectopy During Ablation in the Electrophysiology Lab
02/01/2025
Bradley P. Knight, MD, FACC, FHRS
Electrical stimulation of the vertebral veins using a multielectrode EP catheter may be a promising new technique to provoke PVCs in the EP lab to facilitate mapping and successful catheter ablation.
Electrical stimulation of the vertebral veins using a multielectrode EP catheter may be a promising new technique to provoke PVCs in the EP lab to facilitate mapping and successful catheter ablation.
Electrical stimulation of the...
02/01/2025
EP Lab Digest
Letter from the Editor
Intravascular Hemolysis Related to Pulsed Field Ablation
01/10/2025
Bradley P. Knight, MD, FACC, FHRS
Introduction of this new energy source and the associated electrode catheters designed to deliver PFA has come with the recognition of novel procedural risks and complications that were not considered in the past when using RF or cryo.
Introduction of this new energy source and the associated electrode catheters designed to deliver PFA has come with the recognition of novel procedural risks and complications that were not considered in the past when using RF or cryo.
Introduction of this new energy...
01/10/2025
EP Lab Digest
Letter from the Editor
The Most Significant Updates in Electrophysiology in 2024
12/01/2024
Bradley P. Knight, MD, FACC, FHRS
What were the most significant guideline updates and clinical trials in clinical cardiac electrophysiology in 2024? Here is a list of 8 high-impact guidelines and studies published in 2024.
What were the most significant guideline updates and clinical trials in clinical cardiac electrophysiology in 2024? Here is a list of 8 high-impact guidelines and studies published in 2024.
What were the most significant...
12/01/2024
EP Lab Digest
Letter from the Editor
Does the Presence of an Isoelectric Period Predict the Mechanism of a Post-Ablation Atrial Arrhythmia?
11/01/2024
A study using ultra-high-density mapping of post-ablation atrial arrhythmias teaches us that over one-third of patients who present with an atrial tachycardia that demonstrates an isoelectric period actually have a macroreentrant mechanism.
A study using ultra-high-density mapping of post-ablation atrial arrhythmias teaches us that over one-third of patients who present with an atrial tachycardia that demonstrates an isoelectric period actually have a macroreentrant mechanism.
A study using ultra-high-density...
11/01/2024
EP Lab Digest
Letter from the Editor
How Was a Sham-Controlled Trial for Atrial Fibrillation Ablation in Humans Ever Justified?
09/04/2024
Bradley P. Knight, MD, FACC, FHRS
In September 2024, the first sham-controlled AF ablation trial was published simultaneous with presentation of the study findings at the European Society of Cardiology (ESC) Congress 2024.
In September 2024, the first sham-controlled AF ablation trial was published simultaneous with presentation of the study findings at the European Society of Cardiology (ESC) Congress 2024.
In September 2024, the first...
09/04/2024
EP Lab Digest
Letter from the Editor
Hospital Rankings for Heart and Heart Surgery Need to Include Electrophysiology Procedures in Their Metrics
09/01/2024
Bradley P. Knight, MD, FACC, FHRS
Historically, more resources, attention, and personnel are dedicated to the cardiac operating rooms, cardiac intensive care units, and catheterization laboratories than to the EP laboratories. There are many reasons why.
Historically, more resources, attention, and personnel are dedicated to the cardiac operating rooms, cardiac intensive care units, and catheterization laboratories than to the EP laboratories. There are many reasons why.
Historically, more resources,...
09/01/2024
EP Lab Digest
Letter from the Editor
Reducing the Rate of Serious Adverse Events in the Cardiac Electrophysiology Laboratory From 2% to 1%
08/16/2024
Bradley P. Knight, MD, FACC, FHRS
It is unrealistic to expect zero complications from an invasive procedure. It is also important to learn that trying to lower the rate of serious adverse events from 2% to 1% in the EP lab can require much more than twice the effort.
It is unrealistic to expect zero complications from an invasive procedure. It is also important to learn that trying to lower the rate of serious adverse events from 2% to 1% in the EP lab can require much more than twice the effort.
It is unrealistic to expect zero...
08/16/2024
EP Lab Digest
Letter from the Editor
Are Disease-Modifying Treatments on the Horizon for Patients With Arrhythmogenic Right Ventricular Cardiomyopathy?
07/02/2024
Bradley P. Knight, MD, FACC, FHRS
Gene therapy targeting the underlying desmosomal mutation and approaches to prevent myocardial fibrosis independent of the specific genetic defect by increasing cardiac levels of FGF21 may be on the horizon for patients with ARVC.
Gene therapy targeting the underlying desmosomal mutation and approaches to prevent myocardial fibrosis independent of the specific genetic defect by increasing cardiac levels of FGF21 may be on the horizon for patients with ARVC.
Gene therapy targeting the...
07/02/2024
EP Lab Digest
EPLD April 2025 cover.

Current Issue

April 2025
Volume 24
Issue 4
Current Issue
Issue Archive

Stay in the know.

EP Lab Digest Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use